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• Chronic infection with the hepatitis C virus (HCV) can lead to end-stage liver disease (ESLD) complications including decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC) [1] [2] [3] , with patients in advanced fibrosis stages being at highest risk.
• The availability of effective treatment for these patients is an area of unmet medical need, with standard of care (SoC) based upon a pegylated interferon-alfa and ribavirin (PR) backbone, which is associated with efficacy and tolerability issues [4, 5] .
• Important clinical advances have been made in recent years, with the introduction of direct-acting antivirals (DAAs) that are associated with substantially increased rates of sustained virologic response (SVR), fewer tolerability issues and shorter treatment durations. Daclatasvir is an example of a new generation DAA that has recently been licensed by the European Medicines Agency via accelerated assessment [6] .
• The objective of this study was to assess the cost-effectiveness of daclatasvir plus sofosbuvir (DCV+SOF) versus SoC in treatment-naïve patients with HCV genotypes 1, 3 and 4 and advanced disease (METAVIR score ≥F3).
Methods
• A published Markov model [7-10] was used to estimate the relative cost-effectiveness of HCV treatments over a lifetime horizon in a cohort that were 67% male and had a mean age of 50 years [11-13].
• Patients were distributed across METAVIR fibrosis stages F3 and F4 (78.6% and 21.4%, respectively [12]), and progress through fibrosis stages to ESLD complications and death according to published disease state transition rates [14, 15] (Figure 1 ). • UK-specific costs [16, 17] and health utility estimates [15, [18] [19] [20] were sourced ( Table  1) .
• An annual discount rate of 3.5% was applied. • Increasing the cost-effectiveness threshold to £30,000/QALY resulted in improvements in the likelihood of cost-effectiveness. Predicted probabilities rose to 100% in all comparisons, with the exception of PR in genotype 3 patients, which rose to 40%.
• The largest amount of variability was observed when comparing DCV+SOF to no treatment, due to a larger degree of uncertainty caused by the lack of SVR in patients that are not treated. • At conventional UK cost effectiveness thresholds, treatment with DCV+SOF is estimated to be cost-effective compared to SoC and no treatment in HCV genotypes 1 and 4. In HCV genotype 3, DCV+SOF is predicted to be cost effective compared to no treatment.
• DCV+SOF has demonstrated high rates of efficacy [22] . This analysis supports the use of DCV+SOF in patients with HCV genotypes 1, 3 and 4 and advanced fibrosis, through demonstration of cost-effectiveness against the majority of comparators.
